CAMK2G and cardiac arrhythmia: PRMT1 can reduce calcium/calmodulin‐dependent protein kinase II (CaMKII) activity by methylating arginine residues (e.g., R9 and R275) of CaMKII, hence inhibiting arrhythmia and cardiac hypertrophy resulting from excessive CaMKII activation.